Zhang Ming-Qiang
Merck Sharp & Dohme (MSD), Chaoyang District, Beijing, PR, China.
Methods Mol Biol. 2012;803:297-307. doi: 10.1007/978-1-61779-364-6_20.
Based on analyses of existing small organic drug molecules, a set of "rules-of-thumb" have been devised to assess the likeness of a small molecule under study to those existing drugs in terms of physicochemical and topological properties. These rules can be used to estimate the likelihood of a small molecule to possess the desired efficacy, pharmacokinetic/pharmacodynamic properties, and toxicity profiles to eventually become a drug, and therefore, whether it justifies further experimental work and development. These rules are particularly useful when selecting a chemical starting point for a given project or choosing a chemical series to focus when multiple series are available. Caution should be paid, however, not to overly rely on these rules for decision-making, since these rules are restricted by knowledge of existing drugs. Novel chemotypes and/or targets may be exceptions.
基于对现有有机小分子药物的分析,已制定了一套“经验法则”,以便根据物理化学和拓扑学性质评估所研究的小分子与现有药物的相似性。这些规则可用于估计小分子具有所需疗效、药代动力学/药效学性质和毒性特征以最终成为药物的可能性,因此也可用于判断进一步的实验工作和研发是否合理。当为给定项目选择化学起始点或在有多个系列可供选择时选择要重点关注的化学系列时,这些规则特别有用。然而,应注意不要过度依赖这些规则进行决策,因为这些规则受到现有药物知识的限制。新型化学类型和/或靶点可能是例外情况。